“Overview of the Safety Profile From Efgartigimod Clinical Trials in Participants With Diverse IgG-Mediated Autoimmune Diseases” (2024) SKIN The Journal of Cutaneous Medicine, 8(1), p. s344. doi:10.25251/skin.8.supp.344.